Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04623775 · ClinicalTrials.gov registry record · Phase 2
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
A Phase 2 study of Non-Small Cell Lung Cancer and Metastatic Non Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 2
- Development phase
- 468
- Enrollment target
- 20
- Study locations
NCT04623775 is a Phase 2 study of Non-Small Cell Lung Cancer and Metastatic Non Small Cell Lung Cancer that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 468 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04623775, a Phase 2 study of Non-Small Cell Lung Cancer and Metastatic Non Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 468 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus relatlimab in combination with PDCT improves overall response rate (ORR) when compared to nivolumab plus PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Paclitaxel
- BIOLOGICAL Nivolumab
- BIOLOGICAL Relatlimab
Study Locations (20)
New York
- Local Institution - 0124 - Johnson City
- Local Institution - 0162 - Mineola
- Local Institution - 0128 - New York
- Local Institution - 0165 - New York
- Local Institution - 0097 - The Bronx
California
- Local Institution - 0160 - Duarte
- Local Institution - 0081 - Orange
Florida
- Local Institution - 0153 - Jacksonville
- Local Institution - 0011 - Port Saint Lucie
Kentucky
- Local Institution - 0159 - Lexington
- Local Institution - 0002 - Louisville
Ohio
- Local Institution - 0156 - Cincinnati
- Local Institution - 0155 - Cleveland
Connecticut
- Local Institution - 0139 - New Haven
Georgia
- Local Institution - 0089 - Athens
Kansas
- Local Institution - 0121 - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 468 participants |
| Start Date | 2021-02-17 |
| Est. Completion | 2026-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04623775
The ClinicalTrials.gov registry entry for NCT04623775 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 468 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (29% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT04623775 reports 20 study locations spanning 12 distinct geographic areas - top geographies include New York, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04623775 about?
NCT04623775 is a clinical study titled "A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)". The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus relatlimab in combination with PDCT improves overall response rate (ORR) when compared to nivolumab plus PDCT in particip...
What is the current status of trial NCT04623775?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 468 participants. The study started on 2021-02-17. Estimated completion is 2026-02-27.
What conditions does trial NCT04623775 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT04623775?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Paclitaxel (DRUG), Nivolumab (BIOLOGICAL), Relatlimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04623775?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04623775 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Non-Small Cell Lung Cancer
All registered trials for this condition
Metastatic Non Small Cell Lung Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.